Anton Wellstein

PREVENTION OF METASTATIC OUTGROWTH USING TEAD INHIBITORS

USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE

METHODS OF IDENTIFYING NOVEL PROTEINS AND ANTIGENS IN CANCER CELLS

USE OF GENETIC AND EPIGENETIC MARKERS TO DETECT CELL DEATH

CHRM3 AS A MARKER AND TARGET FOR CANCER THERAPY

SYSTEMS AND METHODS FOR IDENTIFYING AND ISOLATING INVASIVE SUBPOPULATIONS OF CANCER CELLS IN REAL-TIME

TREATMENTS AND METHODS FOR CONTROLLING HYPERTENSION

Treatments of Metabolic Disorders Using FGF Binding Protein 3

Methods of identifying novel proteins and antigens in cancer cells

Compositions and Treatments of Metabolic Disorders Using FGF Binding Protein 3

Compositions and methods for identification of relapse risk and treatment in patients with colorectal cancer

Treatments for lowering glucose levels using FGF binding protein 3

ANTI-PLEIOTROPHIN ANTIBODIES AND METHODS OF USE THEREOF

NOVEL GENES AND PROTEINS THAT HOME TO DEVELOPING MICROVESSELS

Polynucleotides that home to atherosclerotic plaque

METHODS FOR IDENTIFYING TARGETING DOMAINS AND METHOD AND COMPOSITIONS COMPRISING THE SAME

Method for identifying targeting domains and methods and compositions comprising the same

ANTI-PLEIOTROPHIN ANTIBODIES AND METHODS OF USE THEREOF

Anti-pleiotrophin antibodies and methods of use thereof

Genes and proteins that home to developing microvessels

Organ Homing Genes of Cancer Metastases

PLEIOTROPHIN GROWTH FACTOR RECEPTOR FOR THE TREATMENT OF PROLIFERATIVE, VASCULAR AND NEUROLOGICAL DISORDERS

Antibodies that bind to pleiotrophin growth factor receptor

Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders

Coactivators in the diagnosis and treatment of breast cancer

Detection of pleiotrophin